The biggest investor in a nursing home chain can run but not hide from comeuppance for the chain’s alleged role in harms—including deaths—done to hundreds of patients.
Cytokinetics has secured FDA approval for aficamten, its new drug for the treatment of symptomatic obstructive HCM. Aficamten will be sold under the brand name Myqorzo.
PAD in patients with diabetes is common and associated with an increased risk of several adverse events. A new guidance from the American College of Cardiology reviewed this topic at length, identifying areas where care needs to improve.
One of the event's primary takeaways was that interventional cardiology does still attract a healthy number of trainees. However, SCAI sees several ways the specialty can improve to be even more appealing in the future.
PFA has emerged as the preferred ablation strategy for many electrophysiologists, but some questions do remain about its long-term impact. HRS is developing this new registry to be as user-friendly for clinicians as possible.
The ACC and AHA both issued new statements on noninvasive CCTA offerings that use advanced AI to evaluate patients with suspected CAD. These technologies have gained significant momentum in recent years, and experts agree that they represent a game-changing advancement in the world of cardiovascular imaging.
Mass firings on Tuesday led to thousands of workers at the CDC, FDA and NIH losing their jobs, including those working on public health initiatives and vaccine approvals.
Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.
Federal authorities made the announcement on Tuesday. Mangione is still awaiting trial in New York on accusations he murdered UnitedHealthcare’s CEO, Brian Thompson.
The biggest investor in a nursing home chain can run but not hide from comeuppance for the chain’s alleged role in harms—including deaths—done to hundreds of patients.
Cytokinetics has secured FDA approval for aficamten, its new drug for the treatment of symptomatic obstructive HCM. Aficamten will be sold under the brand name Myqorzo.
PAD in patients with diabetes is common and associated with an increased risk of several adverse events. A new guidance from the American College of Cardiology reviewed this topic at length, identifying areas where care needs to improve.
